Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Wang, Bei ^a   Zaidi, Neeha ^a   He, Li Zhen ^b   Zhang, Li ^a   Kuroiwa, Janelle M Y ^a   Keler, Tibor ^b   Steinman, Ralph M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Celldex Therapeutics Inc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DEC HER2 FUSION MONOCLONAL ANTIBODY; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HER2 PROTEIN VACCINE; MONOCLONAL ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG CROSS REACTIVITY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR IMMUNITY; ANIMAL; BREAST TUMOR; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE STRAIN; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, HUMORAL; INTERFERON-GAMMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; POLY I-C; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84862777557     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3135     Document Type: Article

References (61)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475. 10.1038/nrc2656, 19536107.
3. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
4. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994, 1198:165-184.
5. Pupa SM, Menard S, Andreola S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993, 53:5864-5866.
6. Disis M, Calenoff E, McLaughlin G, Murphy A, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston R, Moe R, Cheever M. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994, 54:16-20.
7. Ward RL, Hawkins NJ, Coomber D, Disis ML. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 1999, 60:510-515. 10.1016/S0198-8859(99)00003-8, 10408800.
8. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000, 62:245-252. 10.1023/A:1006438507898, 11072789.
9. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 2002, 9:33-44. 10.1677/erc.0.0090033, 11914181.
10. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994, 54:3387-3390.
11. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995, 181:2109-2117. 10.1084/jem.181.6.2109, 2192068, 7539040.
12. Peiper M, Goedegebuure PS, Izbicki JR, Eberlein TJ. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Anticancer Res 1999, 19:2471-2475.
13. Taylor P, Gerder M, Moros Z, Feldmann M. Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu. Cancer Immunol Immunother 1996, 42:179-184. 10.1007/s002620050268, 8640846.
14. Foy TM, Bannink J, Sutherland RA, McNeill PD, Moulton GG, Smith J, Cheever MA, Grabstein K. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 2001, 19:2598-2606. 10.1016/S0264-410X(00)00493-X, 11257398.
15. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 2003, 21:1317-1326. 10.1016/S0264-410X(02)00741-7, 12615426.
16. Dimitriadis A, Gontinou C, Baxevanis CN, Mamalaki A. The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity. BMC Cancer 2009, 9:386. 10.1186/1471-2407-9-386, 2776603, 19878568.
17. Rohrbach F, Weth R, Kursar M, Sloots A, Mittrucker H-W, Wels WS. Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. J Immunol 2005, 174:5481-5489.
18. Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jager E, Forni G, Cavallo F, Wels WS. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Clin Cancer Res 2008, 14:6933-6943. 10.1158/1078-0432.CCR-08-1257, 18980988.
19. Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res 2009, 15:4612-4621. 10.1158/1078-0432.CCR-08-3321, 19584156.
20. Kim YS, Kim YJ, Lee JM, Han SH, Ko HJ, Park HJ, Pereboev A, Nguyen HH, Kang CY. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Hum Gene Ther 2010, 21:1697-1706. 10.1089/hum.2009.202, 20604681.
21. Thomann JS, Heurtault B, Weidner S, Braye M, Beyrath J, Fournel S, Schuber F, Frisch B. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 2011, 32:4574-4583. 10.1016/j.biomaterials.2011.03.015, 21474175.
22. Zizzari IG, Veglia F, Taurino F, Rahimi H, Quaglino E, Belleudi F, Riccardo F, Antonilli M, Napoletano C, Bellati F, Benedetti-Panici P, Torrisi MR, Frati L, Nuti M, Rughetti A. HER2-based recombinant immunogen to target DCs through FcgammaRs for cancer immunotherapy. J Mol Med (Berl) 2011, 89:1231-1240.
23. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, Nussenzweig MC. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995, 375:151-155. 10.1038/375151a0, 7753172.
24. Inaba K, Swiggard WJ, Inaba M, Meltzer J, Mirza A, Sasagawa T, Nussenzweig MC, Steinman RM. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol 1995, 163:148-156. 10.1006/cimm.1995.1109, 7758125.
25. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz V, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, Steinman RM, Nussenzweig MC. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111. 10.1126/science.1136080, 17204652.
26. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802. 10.1038/nri2173, 17853902.
27. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, Rodriguez A, Clausen BE, Park CG, Trumpfheller C, Steinman RM. Comparable T helper 1 (Th1) and CD8 T-cell immnity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA 2011, 108:2384-2389. 10.1073/pnas.1019547108, 3038758, 21262813.
28. Granelli-Piperno A, Pritsker A, Pack M, Shimeliovich I, Arrighi J-F, Park CG, Trumpfheller C, Piguet V, Moran TM, Steinman RM. Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol 2005, 175:4265-4273. 1378112, 16177066.
29. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, Steinman RM. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000, 151:673-683. 10.1083/jcb.151.3.673, 2185598, 11062267.
30. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194:769-780. 10.1084/jem.194.6.769, 2195961, 11560993.
31. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824. 10.1084/jem.20032220, 2212731, 15024047.
32. Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann N Y Acad Sci 2009, 1174:6-17. 10.1111/j.1749-6632.2009.04933.x, 2933265, 19769731.
33. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002, 196:1627-1638. 10.1084/jem.20021598, 2196060, 12486105.
34. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM. Dendritic cells require a systemic type I interferon response to induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206:1589-1602. 10.1084/jem.20090247, 2715098, 19564349.
35. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, Breton G, Trumpfheller C, Pollak S, Shimeliovich I, Duque-Alarcon A, Pan L, Nelkenbaum A, Salazar AM, Schlesinger SJ, Steinman RM, Sekaly RP. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 2011, 208:2357-2366. 10.1084/jem.20111171, 22065672.
36. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850. 10.1038/nm1592, 17558415.
37. Cornell CJ, Smith KA, Cornwell GG, Burke GP, McIntyre OR. Sytemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man. J Natl Cancer Inst 1976, 57:1211-1216.
38. Morse MA, Chapman R, Powderly J, Blackwell KL, Keler T, Green J, Riggs R, He LZ, Ramakrishna V, Vitale L, Zhao B, Hobeika A, Osada T, Davis TA, Clay TM, Lyerly HK. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self antigens in cancer patients. Clin Cancer Res 2011, 17:4844-4853. 10.1158/1078-0432.CCR-11-0891, 21632857.
39. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011, 29:330-336. 10.1200/JCO.2010.30.7744, 3056467, 21149657.
40. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011, 17:1603-1615. 10.1158/1078-0432.CCR-10-2563, 3071163, 21135147.
41. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol 2010, 12:1071-1077. 10.1093/neuonc/noq071, 3018929, 20615924.
42. Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, Soares H, Huang Y, Schlesinger SJ, Park CG, Nussenzweig MC, Granelli-Piperno A, Steinman RM. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 2006, 203:607-617. 10.1084/jem.20052005, 2118242, 16505141.
43. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999, 163:1037-1044.
44. Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res 2006, 66:5452-5460. 10.1158/0008-5472.CAN-05-4018, 16707474.
45. Gu XG, Schmitt M, Hiasa A, Nagata Y, Ikeda H, Sasaki Y, Akiyoshi K, Sunamoto J, Nakamura H, Kuribayashi K, Shiku H. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 1998, 58:3385-3390.
46. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
47. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, Trajanoski Z, Fridman WH, Galon J. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009, 69:2685-2693. 10.1158/0008-5472.CAN-08-2654, 19258510.
48. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, Schlesinger SJ, Colonna M, Steinman RM. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008, 105:2574-2579. 10.1073/pnas.0711976105, 2268178, 18256187.
49. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998, 10:588-594. 10.1016/S0952-7915(98)80228-8, 9794842.
50. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 2006, 24:519-540. 10.1146/annurev.immunol.23.021704.115825, 16551258.
51. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010, 70:8368-8377. 10.1158/0008-5472.CAN-10-1322, 2970736, 20940398.
52. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002, 8:1014-1018.
53. Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 2000, 20:17-56.
54. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005, 22:371-383. 10.1016/j.immuni.2005.02.003, 15780993.
55. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002, 2:85-95. 10.1038/nri724, 11910899.
56. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109:5346-5354. 10.1182/blood-2006-10-051318, 1890845, 17327412.
57. Quezada S, Simpson T, Peggs K, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony P, Restifo N, Allison J. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010, 207:637-650. 10.1084/jem.20091918, 2839156, 20156971.
58. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010, 207:651-667. 10.1084/jem.20091921, 2839147, 20156973.
59. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005, 65:7007-7012. 10.1158/0008-5472.CAN-05-0938, 16061687.
60. Bozzacco L, Trumpfheller C, Huang Y, Longhi MP, Shimeliovich I, Schauer JD, Park CG, Steinman RM. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. Eur J Immunol 2010, 40:36-46. 2933266, 19830741.
61. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000, 60:3569-3576.